Updates from Syncona and our portfolio companies
Iain McGill introduces Quell Therapeutics, a leader in the new field of T-regulatory cells, and announces their planned expansion to their series A by Syncona making it the largest Series A in the space. Iain discusses Quell’s progress to date and what the financing will enable Quell to achieve
Martin Murphy and Freddie Dear explain why Syncona has expanded Quell’s financing to support the additional pipeline programmes, how they have worked with the Quell team, and their ambition for the company to become a global leader in treating liver transplantation, autoimmune and inflammatory diseases.
Marc Martinez-Llordella, VP Biology at Quell, discusses why liver transplantation is the first programme Quell Therapeutics has selected for entry to the clinic and the advantages of engineered Tregs. Nathalie Belmonte, SVP Research and Translation, discusses Quell’s objective of making a complete cure for liver transplant patients through Tregs, leading to an improvement in patients quality of life and survival. Nathalie also discusses Quell’s new research programmes targeting ALS and Type 1 diabetes
Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with the Sheffield Institute for Translational Neuroscience (SITraN), an international centre of excellence within the University of Sheffield recognised for its ground-breaking work in the fight against neurodegenerative disorders. Under the terms of the agreement, Quell Therapeutics will collaborate in a joint research programme with SITraN to accelerate the validation of Quell’s engineered Treg cell therapy platform for use in the treatment of neuroinflammatory diseases.
Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium), and Senior Clinical Academic, Professor Sir Robert Lechler, Senior Vice President/Provost (Health) and Executive Director of King's Health Partners Academic Health Sciences Centre, to its Board of Directors.
London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with Hannover Medical School (MHH). Under the terms of the agreement, Quell Therapeutics will collaborate in joint research with MHH to accelerate the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.
Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.
Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris talk through the process for founding our innovative cell therapy company, Quell Therapeutics.
Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.